Who we are

Welcome to the webpage of the Human Systems Biology group in the National Institute for Genomic Medicine at Mexico City, INMEGEN. Our group is interdisciplinary and have the objective to develop a systems biology framework to analyze mainly human diseases and metabolic phenotype in microorganisms through the use of computational models and high-throughput technologies. Currently, our laboratory focuses on the analysis of metabolic alterations in cancer cells by the implementation of genome scale metabolic reconstructions and assess the predictions in terms of experimental data at different scales.

Biological Physics Mexico City 2019

from 06-09-2019 to 04-09-2019

Frontier Science at the Intersection of Physics, Math and Biology The BioPhys Mexico City 2019 conference, the third in a biennial series, is intended as an international, multidisciplinary scientific forum to discuss the latest developments in biological physics, including experimental, theoretical and computational methods, from a single molecule perspective to complex multi-component environments. The conference is expected to boost the new paradigm of interdisciplinary approaches converging into specific problems in biological physics.

Digital modeling of metformin and diet interactions on gut-microbiota metabolism in prediabetic patients

Computational and Structural Biotechnology Journal 2026

Juan José Oropeza-Valdez, Cristian Padron-Manrique, Jorge E. Arellano-Villavicencio, Aarón Vázquez-Jiménez, Laura E. Hernández-Juárez, Xavier Soberon, María de Lourdes Reyes-Escogido, Rodolfo Guardado-Mendoza and Osbaldo Resendis-Antonio

Prediabetes confers a high risk of progressing to type 2 diabetes mellitus (T2DM). While metformin, a first-line T2DM therapy, improves glycemic control in prediabetes, its effects on the gut microbiota and host metabolic shifts remain poorly understood. Here, we applied a genome-scale community metabolic modeling to build a personalized “digital microbiota” for analyzing the metabolic activity of gut microbes in 106 samples of Mexican prediabetic patients, distributed among patients without treatment and patients treated with metformin over baseline, 6 and 12 months.